Unlocking The Potential of UBE3C as A Drug Target Or Biomarker

Target Name: UBE3C

NCBI ID: G9690

UBE3C

Unlocking The Potential of UBE3C as A Drug Target Or Biomarker

UBE3C (HECTH2), a protein that belongs to the heparan sulfate proteoglycan (HSPG) family, has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure, which consists of a single transmembrane domain and a N-terminal extracellular domain that is rich in positively charged amino acids, makes it an interesting protein of interest.

Recent studies have shown that UBE3C plays a critical role in various cellular processes, including cell signaling, migration, and invasion. UBE3C has been shown to be involved in several signaling pathways, including the TGF-β pathway, which plays a crucial role in the development and progression of cancer.

Additionally, UBE3C has been shown to be involved in the regulation of cell adhesion and migration. Its presence in the cell surface has been reported to be involved in the interaction between cells and tissues, which is important for the development of tissues and organs and for the regulation of various physiological processes.

Furthermore, UBE3C has been shown to be involved in the regulation of inflammation and immune responses. Its presence in various immune cells has been reported to play a role in the regulation of immune cell function and the regulation of inflammation.

Due to its involvement in several critical cellular processes, UBE3C has been considered as a potential drug target or biomarker for various diseases. The potential targets of UBE3C include cancer, neurodegenerative diseases, and autoimmune disorders.

In cancer, UBE3C has been shown to be involved in the regulation of cell signaling, including the TGF-β pathway. Its presence in this pathway has been shown to play a role in the development and progression of various types of cancer, including breast, ovarian, and colorectal cancer.

In neurodegenerative diseases, UBE3C has been shown to be involved in the regulation of cell adhesion and migration. Its presence in these diseases has been reported to play a role in the development of neurodegeneration and the progression of these diseases.

In autoimmune disorders, UBE3C has been shown to be involved in the regulation of inflammation and immune responses. Its presence in these diseases has been reported to play a role in the development and progression of autoimmune disorders.

Overall, UBE3C is a protein that has been shown to be involved in several critical cellular processes, including cell signaling, migration, and inflammation. Its unique structure and its involvement in several disease-related processes make it an interesting protein of interest as a potential drug target or biomarker. Further studies are needed to fully understand its role in these diseases and to determine its potential as a therapeutic agent.

Protein Name: Ubiquitin Protein Ligase E3C

Functions: E3 ubiquitin-protein ligase that specifically catalyzes 'Lys-29'- and 'Lys-48'-linked polyubiquitin chains (PubMed:11278995, PubMed:12692129, PubMed:16341092, PubMed:16601690, PubMed:24811749, PubMed:24158444, PubMed:25752573, PubMed:25752577, PubMed:34239127, PubMed:33637724, PubMed:32039437). Accepts ubiquitin from the E2 ubiquitin-conjugating enzyme UBE2D1 in the form of a thioester and then directly transfers the ubiquitin to targeted substrates (PubMed:9575161, PubMed:32039437). Associates with the proteasome and promotes elongation of ubiquitin chains on substrates bound to the 26S proteasome (PubMed:24158444, PubMed:28396413, PubMed:31375563). Also catalyzes 'Lys-29'- and 'Lys-48'-linked ubiquitination of 26S proteasome subunit ADRM1/RPN13 in response to proteotoxic stress, impairing the ability of the proteasome to bind and degrade ubiquitin-conjugated proteins (PubMed:24811749, PubMed:31375563). Acts as a negative regulator of autophagy by mediating 'Lys-29'- and 'Lys-48'-linked ubiquitination of PIK3C3/VPS34, promoting its degradation (PubMed:33637724). Can assemble unanchored poly-ubiquitin chains in either 'Lys-29'- or 'Lys-48'-linked polyubiquitin chains; with some preference for 'Lys-48' linkages (PubMed:11278995, PubMed:16601690, PubMed:25752577). Acts as a negative regulator of type I interferon by mediating 'Lys-48'-linked ubiquitination of IRF3 and IRF7, leading to their degradation by the proteasome (PubMed:21167755). Catalyzes ubiquitination and degradation of CAND2 (PubMed:12692129)

The "UBE3C Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UBE3C comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets